Nexsen Advances StrepSure Regulatory Progress and Expands Global Market Strategy
Nexsen Limited (ASX: NXN) delivered notable progress during the March 2026 quarter, driven by developments in its StrepSure diagnostic solution. The company secured clarity on its U.S. regulatory pathway after a successful FDA Q-Submission meeting, confirming the 510(k) route and reducing approval risk. StrepSure offers rapid detection of Group B Streptococcus within 20–30 minutes, addressing a critical need in maternal healthcare where traditional testing is time-consuming. Nexsen also initiated a global expansion strategy, focusing on early entry into markets such as Hong Kong, Malaysia, and India. The company received two government grants, including HK$6 million and AU$0.5 million, supporting regional expansion and neonatal testing capabilities. Operationally, progress toward ISO certification and manufacturing scale-up continued. Financially, Nexsen closed the quarter with AU$5.73 million in cash and operating outflows of AU$1.2 million, providing an estimated funding runway of about five quarters.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Nexsen Advances StrepSure Regulatory Progress and Expands Global Market Strategy
Nexsen Limited (ASX: NXN) delivered notable progress during the March 2026 quarter, driven by developments in its StrepSure diagnostic solution. The company secured clarity on its U.S. regulatory pathway after a successful FDA Q-Submission meeting, confirming the 510(k) route and reducing approval risk. StrepSure offers rapid detection of Group B Streptococcus within 20–30 minutes, addressing a critical need in maternal healthcare where traditional testing is time-consuming. Nexsen also initiated a global expansion strategy, focusing on early entry into markets such as Hong Kong, Malaysia, and India. The company received two government grants, including HK$6 million and AU$0.5 million, supporting regional expansion and neonatal testing capabilities. Operationally, progress toward ISO certification and manufacturing scale-up continued. Financially, Nexsen closed the quarter with AU$5.73 million in cash and operating outflows of AU$1.2 million, providing an estimated funding runway of about five quarters.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au